Refractory Epilepsy Completed Phase 1 / 2 Trials for Thalidomide (DB01041)

IndicationStatusPhase
DBCOND0032649 (Refractory Epilepsy)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01061866Thalidomide Low Threshold in EpilepsyTreatment